Brief: ABIONYX Pharma Announces Subscription Of Equity-Linked Facility With IRIS
May 24 (Reuters) - Abionyx Pharma Sa ABNX.PA :
* ANNOUNCED ON TUESDAY ACCELERATES ITS DEVELOPMENT BY
LAUNCHING A
NEW BIOMANUFACTURING CAMPAIGN BASED ON THE RECENTLY ANNOUNCED
ROBUST INNOVATIVE PROCESS SUPPORTED BY AN EQUITY-LINKED
FINANCING FACILITY
* SUBSCRIPTION OF EQUITY-LINKED FINANCING FACILITY FOR UP TO
EUR
12 MILLION WITH IRIS
Source text for Eikon: ID:nBw8VyC2ha
Further company coverage: ABNX.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Abionyx Pharma SA
See all newsBrief: ABIONYX Pharma And OLON Enter Into Strategic Manufacturing Partnership
France's ABIONYX Pharma H1 net loss widens as financial expenses rise
Brief: ABIONYX Pharma H1 EBIT EUR -2.27 Million
Abionyx jumps as Stifel starts coverage with 'buy'
Cardiovascular drug developer ABIONYX Pharma's H1 revenue falls